Tranexamic Acid for Bleeding Reduction During TURP Surgery

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate, Perioperative Bleeding, Anemia, Postoperative

In brief

Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation. This prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia. Participants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact. The study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.

Key facts

Study ID

NCT07460518

Run by

Hamza Najout

People needed

80

Starts

2026-03-15

Expected to finish

2026-09-01

Last updated by the study team

2026-03-10

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patients aged 50 years or older
• Diagnosed with benign prostatic hyperplasia (BPH)
• Scheduled for elective transurethral resection of the prostate (TURP) under spinal anesthesia
• American Society of Anesthesiologists (ASA) physical status I-III
• Provided written informed consent

You may not qualify if…

• History of thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke)
• Known hypersensitivity to tranexamic acid
• Severe renal impairment (creatinine clearance <30 mL/min)
• Coagulation disorders
• Current anticoagulant therapy not appropriately discontinued
• History of seizure disorder
• Refusal to participate

Where it is running

• Mohammed V Military Teaching Hospital — Rabat, Rabat, Morocco

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.